Target intelligence / Profile preview

Cardiovascular system adaptation (blood pressure reduction)

Molecular classification
Physiological process
01

Overview

The target 'Cardiovascular system adaptation (blood pressure reduction)' refers to the complex physiological mechanisms involved in regulating blood pressure in the body. This is not a single molecular target but rather a comprehensive process involving multiple systems, pathways, and molecular targets. Key regulatory systems include the Renin-Angiotensin-Aldosterone System (RAAS), the Natriuretic Peptide System (involving ANP, BNP, CNP, and their receptors NPR1, NPR2, NPR3), and various renal ion channels and transporters (e.g., NHE3, NKCC2, NCC, ENaC, Pendrin). Blood pressure regulation is also influenced by genetic and epigenetic factors, such as specific microRNAs and lncRNA polymorphisms. Understanding these integrated mechanisms is crucial for developing therapeutic strategies to reduce blood pressure and manage conditions like hypertension and chronic heart failure.

02

Mechanism of action

Mechanisms of action for therapies designed to achieve cardiovascular system adaptation (blood pressure reduction) involve modulating key regulatory systems such as the Renin-Angiotensin-Aldosterone System (RAAS) and the Natriuretic Peptide System, inhibiting specific enzymes (e.g., neprilysin), modulating renal ion channels and transporters, and potentially targeting specific 'hub genes' involved in blood pressure regulation.

03

Biological functions

Blood pressure regulationBody fluid homeostasisElectrolyte balance
04

Disease associations

Hypertension (associated with overactivation of RAAS)Chronic heart failure
05

Safety considerations

Not explicitly mentioned for the overall physiological process itself; safety concerns would arise from specific therapeutic interventions that modulate this process.
06

Interacting drugs

Angiotensin Receptor-Neprilysin Inhibitors
07

Biomarkers

MicroRNAs (e.g., miR-11, miR-22, miR-92a, miR-222) elevated in high blood pressureGenetic polymorphisms in lncRNAs (e.g., rs133049, rs10757274, rs2383207, rs10757278) associated with hypertension risk

Beyond the preview

Go deeper on Cardiovascular system adaptation (blood pressure reduction).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cardiovascular system adaptation (blood pressure reduction).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call